According to the KEGG research findings (Figure 3B), the pathways of AA for the treatment of AS primarily involve lipid metabolism-related signals (lipids and atherosclerosis and PPARγ signaling pathways) and inflammatory response-related signals (IL-17 and TNF signaling pathways). This evidence concerns the gene IL17A and atherosclerosis.